SCHEMBL2900568

SCHEMBL2900568

COc1cc(S(=O)(=O)c2ccccc2)ccc1[N+](=O)[O-]

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.57
RAB9A P51151 2/20 0.57
S1PR4 O95977 1/20 0.57
MAPT P10636 1/20 0.57
S1PR1 P21453 1/20 0.57
GFER P55789 1/20 0.57
PAX8 Q06710 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
ALDH1A1 P00352 3/20 0.56
TDP1 Q9NUW8 1/20 0.56
POLB P06746 1/20 0.53
TSHR P16473 1/20 0.53
KMT2A Q03164 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
LMNA P02545 1/20 0.50
HTR6 P50406 1/20 0.49
HPGD P15428 2/20 0.48
KIF18A Q8NI77 1/20 0.48
GAA P10253 2/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8973591 0.88 ALDH1A1 (0.61) MAPK1RAB9AS1PR4MAPTS1PR1
SCHEMBL4608240 0.85 TXNRD1 (0.60) MAPK1RAB9AS1PR4MAPTS1PR1
SCHEMBL30184523 0.81 SMN1; SMN2 (0.54) MAPK1MAPTALDH1A1TDP1POLB
SCHEMBL6522436 0.81 SMN1; SMN2 (0.54) MAPK1MAPTALDH1A1TDP1POLB
SCHEMBL16797504 0.80 MAPK1 (0.81) MAPK1MAPTNPSR1ALDH1A1TDP1
SCHEMBL15824942 0.80 ALDH1A1 (0.51) MAPK1RAB9AS1PR4MAPTS1PR1
SCHEMBL15823469 0.80 ALDH1A1 (0.54) MAPK1MAPTALDH1A1TDP1POLB
SCHEMBL30871423 0.80 CA2 (0.56) MAPTALDH1A1TDP1POLBKMT2A
SCHEMBL10911114 0.80 ALDH1A1 (0.51) MAPK1RAB9AS1PR4MAPTS1PR1
SCHEMBL30612682 0.80 ALDH1A1 (0.54) MAPK1MAPTALDH1A1TDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797051-B1 BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES HOFFMANN LA ROCHE (CH) 2010-08-11 EP disclosed
EP-1797051-B1 BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES HOFFMANN LA ROCHE (CH) 2010-08-11 EP disclosed
EP-1059927-B1 CHEMICAL COMPOUNDS AND THEIR USE TO ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY ASTRAZENECA AB (SE) 2008-07-30 EP disclosed
US-7378415-B2 Benzoxazine and quinoxaline derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2008-05-27 US disclosed
US-7378415-B2 Benzoxazine and quinoxaline derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2008-05-27 US disclosed
US-7378415-B2 Benzoxazine and quinoxaline derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2008-05-27 US disclosed
EP-1797051-A1 BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES F. Hoffmann-Roche AG (CH) 2007-06-20 EP disclosed
US-20060106012-A1 Benzoxazine and quinoxaline derivatives and uses thereof ROCHE PALO ALTO LLC 2006-05-18 US disclosed
WO-2006037481-A1 BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES F.HOFFMANN-LA ROCHE AG (CH) 2006-04-13 WO disclosed
US-6369273-B1 ARYL ALCOHOLS OR ESTERS FOR ELEVATION OF PYRUVATE DHYDROGENASE ASTRAZENECA AB (SE) 2002-04-09 US disclosed
EP-0617010-B1 Therapeutic compounds ASTRAZENECA AB (SE) 2002-01-09 EP disclosed
EP-1059927-A1 CHEMICAL COMPOUNDS AND THEIR USE TO ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY AstraZeneca AB (SE) 2000-12-20 EP disclosed
WO-1999044618-A1 CHEMICAL COMPOUNDS AND THEIR USE TO ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY ASTRAZENECA AB (SE) 1999-09-10 WO disclosed
US-5900432-A Therapeutic N-(4-benzoyl-2-methyl-phenyl)-3,3,3-trifluoro-2-hydroxy-2-methyl-propanamides ZENECA LIMITED (GB) 1999-05-04 US disclosed
US-5482969-A Certain N(4-benzoyl-2-phenyl)-3- trifluoro-2-hydroxy-propanamide derivatives ZENECA LIMITED (GB) 1996-01-09 US disclosed
EP-0617010-A1 Therapeutic compounds ZENECA LIMITED (GB) 1994-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106012-A1 Benzoxazine and quinoxaline derivatives and uses thereof XDH, PDHX, HAX1 MAPK1 2434/4885RAB9A 1540/4885S1PR4 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.